" class="no-js "lang="en-US"> Astellas Pharma - Medtech Alert
Tuesday, April 16, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Astellas Pharma | Pharmtech Focus

Astellas Pharma

About Astellas Pharma

Astellas Pharma

Astellas Pharma is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.

Related Story

News

 Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders | MTA

Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders

June 15 2023

Astellas Pharma and Cullgen have announced a research collaboration and exclusive option agreement to discover […]

News

 Astellas Submits New Drug Application for Zolbetuximab in Japan | MTA

Astellas Submits New Drug Application for Zolbetuximab in Japan

June 12 2023

Astellas Pharma has announced the submission of a New Drug Application (NDA) on June 9, […]

Drug Development

 Gilteritinib as Maintenance Therapy Demonstrated Benefit in Subgroups of FLT3-ITD Acute Myeloid Leukemia Patients | MTA

Gilteritinib as Maintenance Therapy Demonstrated Benefit in Subgroups of FLT3-ITD Acute Myeloid Leukemia Patients

June 12 2023

Astellas Pharma and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) has presented […]

Drug Development

 Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 | MTA

Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430

June 9 2023

Astellas Pharma and Kate Therapeutics have announced an exclusive license agreement to develop and commercialize KT430. […]

News

 Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field | MTA

Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field

May 16 2023

Sony Corporation and Astellas Pharma today announced that they have entered into a collaborative research […]

News

 MIMETAS and Astellas Enter into Strategic Partnership | MTA

MIMETAS and Astellas Enter into Strategic Partnership

March 29 2023

MIMETAS, a global leader in human disease modeling, announces that it has entered into a […]

Diseases

 Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer | MTA

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

March 17 2023

Pfizer and Astellas Pharma have announced positive topline results from the Phase 3 EMBARK trial […]

Clinical Trials

 Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib | MTA

Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib

March 9 2023

Astellas Pharma and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) today announced […]

Drug Development

 Astellas Provides Update on Fezolinetant New Drug Application in U.S. | MTA

Astellas Provides Update on Fezolinetant New Drug Application in U.S.

February 20 2023

Astellas Pharma has announced the US Food and Drug Administration (FDA) notified the company that […]

Industry News

 Mogrify and Astellas Announce Collaboration to Conduct Research on in Vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss | Pharmtech Focus

Mogrify and Astellas Announce Collaboration to Conduct Research on in Vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss

July 5 2022

Mogrify Limited (CEO: Darrin M. Disley, Ph.D., “Mogrify®”), a biopharmaceutical company transforming the lives of […]

Diseases

 Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology | Pharmtech Focus

Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology

June 1 2022

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and GO Therapeutics, Inc. (Co-Founder […]